Center for Biosimilars

Denosumab, Golimumab Biosimilars Clear Major Regulatory Milestones in Europe, As US Hurdles Remain

Biosimilar developers achieve key European approvals for denosumab and golimumab, enhancing patient access while facing US ...
Center for Biosimilars

BioRationality: FDA Issues New Guidance on Promotional Communications for Biosimilar Products

FDA's new guidance clarifies promotional practices for biosimilars, ensuring accurate marketing and preventing misleading ...
Center for Biosimilars

Biosimilar QL1207 Demonstrates Equivalent Efficacy and Safety in DME

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...
Center for Biosimilars

Swiss Analysis Shows Biosimilars Cut Costs but Longer-Interval Options Lead Savings

Explore the cost-effectiveness of ranibizumab biosimilars versus aflibercept in treating AMD and DME, revealing significant ...
centerforbiosimilars

Sarfaraz K. Niazi, PhD

Biosimilar Romiplostim Shows Equivalence to Reference Product for Chronic ITP ...
centerforbiosimilars

Skylar Jeremias

Medicare Price Negotiations Will Slow Biosimilar Momentum, Widening Market Gap ...
centerforbiosimilars

Sarfarzaz K. Niazi

Medicare Price Negotiations Will Slow Biosimilar Momentum, Widening Market Gap ...
centerforbiosimilars

Saro Arakelians, PharmD

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.
centerforbiosimilars

Paul Cornes, BM, BCH, MA, MRCP, FRCR

Medicare Price Negotiations Will Slow Biosimilar Momentum, Widening Market Gap ...
centerforbiosimilars

Christopher M. Bruno, JD

Medicare Price Negotiations Will Slow Biosimilar Momentum, Widening Market Gap ...